Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper Post navigationPreviousPrevious post:Anavex to Present at Sigma-1 Receptors SymposiumNextNext post:Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory BoardRelated PostsAnavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s DiseaseApril 23, 2020Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19March 31, 2020Anavex Life Sciences to Webcast 2020 Annual Meeting of ShareholdersMarch 23, 2020
Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseJune 4, 2020
Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s DiseaseApril 23, 2020
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19March 31, 2020
